Raeto T. Strebel
Papers
1
Total Citations
32
H-Index
1
About
Raeto T. Strebel is a leading urologic oncologist whose research focuses on advancing treatment paradigms for muscle-invasive bladder cancer through perioperative chemoimmunotherapy. His major contribution lies in pioneering the combination of immune checkpoint inhibitors with standard chemotherapy, as demonstrated in the landmark SAKK 06/17 phase II trial. This work investigates the integration of durvalumab with cisplatin/gemcitabine before surgery for operable muscle-invasive urothelial carcinoma, addressing the critical need to reduce high relapse rates despite standard neoadjuvant chemotherapy. Strebel’s research has garnered significant attention, with his most cited paper accumulating 32 citations, reflecting the field’s interest in improving outcomes through immunotherapy combinations. His contributions are particularly notable for their potential to transform perioperative management, offering patients a more effective treatment strategy. As a key investigator in the Swiss Group for Clinical Cancer Research (SAKK), Strebel’s work bridges the gap between clinical trial innovation and real-world application, making him a respected voice in urologic oncology. For students and researchers, his studies exemplify the rigorous design of single-arm phase II trials to generate preliminary evidence for novel therapeutic approaches in high-risk bladder cancer.
Research Focus
Key Achievements
Top Papers
- 1